Life Tech to Commercialize Stem Cell Technologies from CDI | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today announced a commercialization deal covering three stem cell technologies from Cellular Dynamics International for the consistent development and growth of human iPS cells for research and bioproduction.

Life Tech will commercialize CDI's Essential 8 Medium, Vitronectin, and Episomal iPSC Reprogramming Vectors, which together address several challenges associated with developing relevant cells, the Carlsbad, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.